News | August 11, 2022
Lincoln Pharmaceuticals Q1 FY23 consolidated profit up at Rs. 15.01 Cr
The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Subscribe To Our Newsletter & Stay Updated
